Pharmaceutical Biotechnology Pv Publication Pdf -

Traditional pharmaceuticals are small, chemically stable, and often taken orally. Biotech drugs (biologics) are massive proteins that cannot survive stomach acid and must be injected. While small molecules diffuse throughout the body, biologics are highly specific, reducing off-target side effects. For example, statins (small molecules) lower cholesterol broadly, whereas PCSK9 inhibitors (monoclonal antibodies) target a single protein in the liver with extreme precision.

Monoclonal antibody (mAb) technology represents another pillar. These Y-shaped proteins are designed to bind to specific antigens (e.g., cancer cell markers). By attaching toxins or immune activators to these antibodies, biotechnologists created "guided missiles" like Rituximab (for lymphoma) and Trastuzumab (for breast cancer), which kill malignant cells while sparing healthy tissue. pharmaceutical biotechnology pv publication pdf

Biologics pose unique regulatory hurdles. The FDA’s Center for Biologics Evaluation and Research (CBER) oversees these products. Unlike generic small molecules, there is no such thing as a true "generic biologic"; instead, we have biosimilars , which are highly similar but not identical due to the inherent variability of living systems. By attaching toxins or immune activators to these